BG103334A - Antiviral vectors - Google Patents
Antiviral vectorsInfo
- Publication number
- BG103334A BG103334A BG103334A BG10333499A BG103334A BG 103334 A BG103334 A BG 103334A BG 103334 A BG103334 A BG 103334A BG 10333499 A BG10333499 A BG 10333499A BG 103334 A BG103334 A BG 103334A
- Authority
- BG
- Bulgaria
- Prior art keywords
- vector particles
- antiviral
- vectors
- antiviral vectors
- consitructed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
PCT/GB1997/002858 WO1998017816A1 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
BG103334A true BG103334A (en) | 2000-06-30 |
Family
ID=10801598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG103334A BG103334A (en) | 1996-10-17 | 1999-04-14 | Antiviral vectors |
Country Status (18)
Country | Link |
---|---|
US (1) | US6235522B1 (zh) |
EP (1) | EP0939827B1 (zh) |
JP (1) | JP2001502903A (zh) |
KR (1) | KR20000049250A (zh) |
CN (1) | CN1195864C (zh) |
AT (1) | ATE520783T1 (zh) |
AU (1) | AU737801B2 (zh) |
BG (1) | BG103334A (zh) |
CA (1) | CA2268271A1 (zh) |
CZ (1) | CZ137299A3 (zh) |
GB (2) | GB9621680D0 (zh) |
HK (1) | HK1018481A1 (zh) |
HU (1) | HUP0000442A3 (zh) |
IL (1) | IL128564A0 (zh) |
NO (1) | NO991742D0 (zh) |
NZ (1) | NZ334522A (zh) |
PL (1) | PL332876A1 (zh) |
WO (1) | WO1998017816A1 (zh) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
CN1247788C (zh) | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
ES2245042T3 (es) | 1997-09-24 | 2005-12-16 | The Regents Of The University Of California | Vectores de lentivirus de no primates y sistemas de empaquetamiento. |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
AU4830899A (en) | 1998-06-24 | 2000-01-10 | Musc Foundation For Research Development | Tissue-specific and target rna-specific ribozymes |
US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
CA2370103C (en) | 1999-04-29 | 2011-08-02 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
EP1083230A1 (en) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Viral replicons and viruses dependent on inducing agents |
JP4540033B2 (ja) | 1999-10-22 | 2010-09-08 | サノフィ パストゥール リミテッド | 腫瘍抗原に対する免疫応答を誘発および/または増強する方法 |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
EP1702983A3 (en) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
US7101541B2 (en) | 2000-05-19 | 2006-09-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution |
WO2002034929A2 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
WO2002086064A2 (en) * | 2001-04-20 | 2002-10-31 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
US20030039636A1 (en) * | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
WO2003012054A2 (en) | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
JP2005504539A (ja) * | 2001-10-02 | 2005-02-17 | インスティテュット クレイトン ド ラ リシェルシュ | 制限発現レンチウイルス性ベクターに関連する方法及び組成物並びにその応用 |
WO2003085087A2 (en) | 2002-04-09 | 2003-10-16 | Aventis Pasteur, Limited | Modified cea nucleic acid and expression vectors |
ES2634424T3 (es) | 2002-02-01 | 2017-09-27 | Oxford Biomedica (Uk) Limited | Vector multicistrónico lentivírico |
EP1499736B1 (en) * | 2002-04-26 | 2009-03-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
US20050014166A1 (en) * | 2002-11-22 | 2005-01-20 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
WO2005030927A2 (en) * | 2003-09-23 | 2005-04-07 | Uab Research Foundation | Methods and compositions for in vivo inflammation monitoring |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
JP2007535329A (ja) * | 2004-04-29 | 2007-12-06 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 細胞接着性を増強する方法および組成物 |
US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
HUE063051T2 (hu) | 2013-02-15 | 2023-12-28 | Bioverativ Therapeutics Inc | Optimalizált VIII. faktor gén |
WO2014142235A1 (ja) * | 2013-03-13 | 2014-09-18 | Li Zhong | 微小胞及びその製造方法 |
WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
BR112018015659A2 (pt) | 2016-02-01 | 2018-12-26 | Bioverativ Therapeutics Inc | genes otimizados do fator viii |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CA3040253A1 (en) | 2016-10-12 | 2018-04-19 | Bioverativ Usa Inc. | Anti-c1s antibodies and methods of use thereof |
US11332521B2 (en) | 2016-11-07 | 2022-05-17 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
AU2018291081A1 (en) | 2017-06-27 | 2020-01-16 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies for treating cancers |
EP3645563A4 (en) | 2017-06-27 | 2021-03-17 | Neuracle Science Co., Ltd | ANTI-FAM19A5 ANTIBODIES AND THEIR USES |
JP7034499B2 (ja) | 2017-06-27 | 2022-03-14 | ニューラクル サイエンス カンパニー リミテッド | 線維症の治療のための抗fam19a5抗体の用途 |
KR102472683B1 (ko) | 2017-06-27 | 2022-12-01 | 주식회사 뉴라클사이언스 | 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도 |
US11597917B2 (en) | 2017-07-06 | 2023-03-07 | The Medical College Of Wisconsin, Inc. | In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders |
CN111527105A (zh) | 2017-10-11 | 2020-08-11 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
MX2020008152A (es) | 2018-02-01 | 2020-11-24 | Bioverativ Therapeutics Inc | Uso de vectores lentivirales que expresan el factor viii. |
US11634484B2 (en) | 2018-04-24 | 2023-04-25 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain |
AU2019265888A1 (en) | 2018-05-10 | 2020-11-26 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
EP3841124A4 (en) | 2018-06-29 | 2022-03-23 | ApitBio, Inc. | ANTI-L1CAM ANTIBODIES AND THEIR USES |
KR20210093950A (ko) | 2018-11-16 | 2021-07-28 | 네오이뮨텍, 인코퍼레이티드 | Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법 |
SG11202105880TA (en) | 2018-12-06 | 2021-07-29 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor ix |
KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
CA3152600A1 (en) | 2019-09-30 | 2021-04-08 | Andrew KROETSCH | Lentiviral vector formulations |
CN114945409A (zh) | 2020-01-13 | 2022-08-26 | 新免疫技术有限公司 | 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法 |
EP4093752A2 (en) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimeric polypeptides |
EP4093751A1 (en) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimeric polypeptides |
JP2023512657A (ja) | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
AU2021297965A1 (en) | 2020-06-24 | 2023-02-23 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor VIII from preparations of lentiviral vectors modified to express said protein |
US20230398216A1 (en) | 2020-10-22 | 2023-12-14 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
KR20230098201A (ko) | 2020-10-26 | 2023-07-03 | 네오이뮨텍, 인코퍼레이티드 | 줄기 세포 동원의 유도 방법 |
KR20230104176A (ko) | 2020-11-02 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | 코로나바이러스의 치료를 위한 인터류킨-7의 용도 |
EP4240408A1 (en) | 2020-11-05 | 2023-09-13 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine |
WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
CA3177712A1 (en) | 2021-06-02 | 2022-12-02 | Lyell Immunopharma, Inc. | Nr4a-deficient cells expressing c-jun and uses thereof |
CN118019758A (zh) | 2021-09-30 | 2024-05-10 | 比奥维拉迪维治疗股份有限公司 | 编码免疫原性降低的因子viii多肽的核酸 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
CA2109579A1 (en) * | 1991-05-29 | 1992-12-10 | Julianna Lisziewicz | Eukaryotic expression vectors with regulation of rna processing |
WO1995030755A1 (fr) * | 1994-05-10 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production |
WO1995032300A1 (en) * | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
EP0817858B1 (en) | 1995-03-09 | 2003-04-23 | Austrian Nordic Biotherapeutics AG | Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy |
GB9510272D0 (en) * | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
AU3212197A (en) * | 1996-06-20 | 1998-01-07 | Salk Institute For Biological Studies, The | Modular assembly retroviral vectors and uses thereof |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Application Discontinuation
- 1997-10-17 CA CA002268271A patent/CA2268271A1/en not_active Abandoned
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
- 1997-10-17 EP EP97909437A patent/EP0939827B1/en not_active Expired - Lifetime
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/en not_active Application Discontinuation
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
-
1999
- 1999-04-13 NO NO991742A patent/NO991742D0/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
- 1999-08-17 HK HK99103561A patent/HK1018481A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO991742L (no) | 1999-04-13 |
EP0939827A1 (en) | 1999-09-08 |
AU4712397A (en) | 1998-05-15 |
CN1195864C (zh) | 2005-04-06 |
GB2331522A (en) | 1999-05-26 |
CN1234075A (zh) | 1999-11-03 |
JP2001502903A (ja) | 2001-03-06 |
ATE520783T1 (de) | 2011-09-15 |
EP0939827B1 (en) | 2011-08-17 |
NZ334522A (en) | 2001-11-30 |
GB9621680D0 (en) | 1996-12-11 |
HK1018481A1 (en) | 1999-12-24 |
AU737801B2 (en) | 2001-08-30 |
GB2331522B (en) | 2001-05-23 |
HUP0000442A3 (en) | 2001-09-28 |
WO1998017816A1 (en) | 1998-04-30 |
NO991742D0 (no) | 1999-04-13 |
US6235522B1 (en) | 2001-05-22 |
CA2268271A1 (en) | 1998-04-30 |
CZ137299A3 (cs) | 1999-07-14 |
PL332876A1 (en) | 1999-10-25 |
GB9903117D0 (en) | 1999-04-07 |
HUP0000442A2 (hu) | 2000-06-28 |
IL128564A0 (en) | 2000-01-31 |
KR20000049250A (ko) | 2000-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG103334A (en) | Antiviral vectors | |
BG103397A (en) | Retroviral vectors | |
GB9510272D0 (en) | Retroviral vectors | |
BG102048A (en) | Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors | |
MY119031A (en) | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses | |
EP0702716A4 (en) | GENTHERAPY FOR HIV INFECTION AND AIDS WITH THE AID OF RIBOZYMS | |
CA2328404A1 (en) | Novel lentiviral packaging cells | |
CA2011878A1 (en) | Immunogenic regions on the e7 protein of human papillomavirus type 16 | |
CA2051288A1 (en) | Viral targeted destruction of neoplastic cells | |
DK631688D0 (da) | 2',3'-dideoxy-2'-fluornucleosider, fremstillingen deraf samt praeparater indeholdende samme | |
AU3258295A (en) | Retroviral vector hybrids and the use thereof for gene transfer | |
ATE228569T1 (de) | Defekte verpackende nicht-oncoviren vektoren aus mpmv | |
EP0801575A4 (en) | RETROVIRAL VECTORS FOR EXPRESSION IN EMBRYONIC CELLS | |
EP0736600A3 (en) | Use of an immunodeficiency suppressing virus which suppresses lymphokines (ISL) to prevent viral replicas, in particular those of retroviruses | |
PT975783E (pt) | "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas" | |
WO2000001835A3 (en) | Targeted integration into chromosomes using retroviral vectors | |
DE3476784D1 (en) | Therapeutic compositions endowed with antiviral activity | |
AU7289587A (en) | Immunosuppressive factor from human immunodeficiency virus (hiv) or hiv infected cells or cell lines, its use, corresponding antibodies and their use | |
WO1999034006A3 (en) | A method for the positive selection of cd4+ t-lymphocytes transduced with anti-hiv genes | |
WO1995025806A3 (en) | Packaging-deficient lentiviruses | |
AU4767093A (en) | Peptides derived from an immunosuppressive region in the retroviral genome | |
CA2199131A1 (en) | Retroviral vector hybrids and the use thereof for gene transfer | |
AU1275095A (en) | Antiviral composition of viral protein trans-dominant variants | |
AU7052291A (en) | Genetic protection of animals against infection by the bovine leukemia virus, and provirus and recombinant virus derived from this virus |